STOCK TITAN

Femasys Q3 sales fall to $405K as operating loss widens

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Femasys Inc. reported third-quarter 2026 sales of $404,597, compared with $729,394 a year earlier. Its operating loss was $4,450,010, versus $3,653,768, and its net loss was $4,564,815, versus $4,194,821. For the first nine months, net loss was $8,187,810, compared with $14,677,582; 2026 results included gains from changes in the fair value of conversion option and warrant liabilities.

Femasys said a $30 million private placement closed in mid-August 2026 supports commercial-team recruitment. It reported that third-quarter U.S. sales increased slightly despite significant funding constraints before the financing, and cited healthcare-system partnerships and initial sales achieved with limited resources. The company is advancing FemBloc toward U.S. FDA approval through the ongoing FINALE pivotal trial.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month net loss narrowed to $8,187,810 from $14,677,582.

Negative

  • Moderate pointThird-quarter sales were $404,597, compared with $729,394 a year earlier.
  • Moderate pointThird-quarter operating loss was $4,450,010, versus $3,653,768 a year earlier.

Filing Explained

At September 30, Femasys reported $23,913,946 in cash and cash equivalents after the mid-August private placement.

This 8-K furnishes Femasys’s third-quarter 2026 results and reports that common shares outstanding increased from 2,980,254 at December 31, 2025, to 8,656,277 at September 30, 2026.

For a holder whose share count did not change, the larger outstanding share base means a smaller percentage ownership of the company.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter sales $404,597 Three months ended September 30, 2026; $729,394 in 2025
Third-quarter operating loss $4,450,010 Three months ended September 30, 2026; $3,653,768 in 2025
Third-quarter net loss $4,564,815 Three months ended September 30, 2026; $4,194,821 in 2025
Nine-month net loss $8,187,810 Nine months ended September 30, 2026; $14,677,582 in 2025
Private placement $30 million Closed in mid-August 2026; supports commercial-team build-out
Cash and cash equivalents $23,913,946 As of September 30, 2026
Intratubal Insemination medical
"FemaSeed® Intratubal Insemination"
Intratubal insemination is a fertility procedure in which sperm are placed directly into a woman's fallopian tube to increase the chance of fertilization, often using a thin catheter passed through the cervix or during laparoscopy. For investors, it signals demand for specialized medical services, devices and clinic capacity—like delivering seed directly into a garden bed to boost crop odds—and can affect revenue, reimbursement and regulatory risk in the fertility-care market.
pivotal trial medical
"ongoing FINALE pivotal trial"
A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.
conversion option liability financial
"Change in fair value of Conversion Option liability"
An accounting entry recording the value of a company’s obligation tied to a financial instrument that can be converted into shares, such as convertible bonds or preferred stock. Think of it like a coupon that could be redeemed for company ownership: it sits on the balance sheet as a potential claim and matters to investors because conversion can dilute existing stock, change debt-versus-equity ratios, and alter earnings-per-share and credit metrics.
warrants liabilities financial
"Change in fair value of Warrants liabilities"
Warrants liabilities are obligations a company records when it has issued warrants—contracts that give holders the right to buy stock or receive cash—but the terms make the company responsible for future payments or share changes. For investors, these items matter because they sit on the balance sheet like a potential bill or promise: they can dilute existing owners, create future cash needs, and cause earnings to swing as the warrants’ value changes, similar to a coupon that might force a store to pay out later.
Sales $404,597 Compared with $729,394 in 2025
Operating loss $4,450,010 Compared with $3,653,768 in 2025
Net loss $4,564,815 Compared with $4,194,821 in 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were FEMY's sales in the third quarter of 2026?

Femasys reported third-quarter sales of $404,597 for the three months ended September 30, 2026, compared with $729,394 for the same period in 2025. Sales for the first nine months of 2026 were $1,161,313, compared with $1,479,926 a year earlier.

What was FEMY's net loss for the first nine months of 2026?

Femasys reported a net loss of $8,187,810 for the nine months ended September 30, 2026, compared with $14,677,582 for the same period in 2025. The 2026 results included gains from changes in the fair value of conversion option and warrant liabilities.

How will Femasys use its $30 million private placement?

Femasys said the $30 million private placement, which closed in mid-August 2026, supports building out its commercial team to drive U.S. sales growth. The company said it had been recruiting commercial professionals with OB/GYN expertise and established relationships.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

Femasys Inc.
(Exact name of registrant as specified in its charter)
Delaware
 
001-40492
 
11-3713499
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

3950 Johns Creek Court, Suite 100
Suwanee, Georgia
 
30024
(Address of principal executive offices)
 
(Zip Code)

(770) 500-3910
(Registrant’s telephone number, including area code)

n/a
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
 
Trading
Symbol(s)
 
Name of each
exchange
on which registered
Common Stock, par value $0.001 per share
 
FEMY
  The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒



Item 2.02
Results of Operations and Financial Condition.
Other Events

On November 13, 2026 Femasys Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.

Exhibit
No.
Description


99.1
Press Release of Femasys Inc. dated November 13, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Femasys Inc.

By:
/s/ Kathy Lee-Sepsick

Names: Kathy Lee-Sepsick

Title: Chief Executive Officer
Date: November 13, 2026





Exhibit 99.1

Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update

-- $30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financing --

ATLANTA, November 13, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.

Corporate Highlights from 3Q 2026 to date


•
Completed $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the FemaSeed® fertility portfolio to OB/GYNs, and to fund the FemBloc® pivotal trial to support U.S. approval.

•
Highlights for the FemaSeed Fertility Portfolio (Diagnostics: FemVue® for her and SpermVueTM for him; first-step treatment: FemaSeed and FemSperm®):

o
Announced a partnership with both UNC Health and Minnesota Women’s Care to introduce the entire portfolio across its OB/GYN practice locations.

o
Announced a partnership with CapexMD to expand patient access through financing solutions and SandsRx Pharmacy for medications to support treatment timing.

•
Highlights for FemBloc Permanent Birth Control:

o
Issuance of patents in the U.S. and key international markets that expand intellectual property protection for the blended polymer component.

o
Received FDA approval of the modular premarket approval (PMA) submission approach.

o
Announced the number of actively enrolling sites in the FINALE trial to support U.S. approval doubled to twelve sites.

“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “With U.S. fertility rates at historic lows, there is an urgent need to bring treatment to the OB/GYN office, where women already seek care. Our portfolio enables these physicians to offer a complete pathway from diagnostics through first-step treatment, supported by partnerships that simplify access to patient financing and fertility medications. Since closing the financing, we have been successfully recruiting commercial professionals with deep OB/GYN expertise and established relationships. Healthcare system partnerships and initial sales achieved with limited resources demonstrate the commercial potential of our comprehensive fertility portfolio. These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”


Financial Results for Quarter Ended September 30, 2026


•
Sales in the U.S. increased slightly to $347,039 in 2026 from $336,594 in 2025, while overall sales decreased by $324,797, or 44.5%, to $404,597 from $729,394. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.

•
Research and development expenses increased by $560,905, or 40.6%, to $1,942,927 in 2026 compared to $1,382,022 in 2025, primarily reflecting the transition of development products into inventory to support commercialization during 2025, and increased clinical costs and compensation costs during 2026.

•
Net loss was $4,564,815, or ($0.53) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2026, compared to a net loss of $4,194,821, or ($2.05) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2025.

Financial Results for Nine Months Ended September 30, 2026


•
Sales in the U.S. increased slightly to $1,038,997 in 2026 from $1,015,168 in 2025, while overall sales decreased by $318,613, or 21.5%, to $1,161,313 from $1,479,926. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.

•
Research and development expenses decreased by $565,717, or 9.8%, to $5,199,206 in 2026 compared to $5,764,923 in 2025, primarily reflecting lower compensation costs, regulatory fees and outside consultant costs, partially offset by increased clinical costs and material and development costs.

•
Net loss was $8,187,810, or ($1.59) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2026, compared to a net loss of $14,677,582, or ($9.25) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2025.

•
Cash and cash equivalents as of September 30, 2026, were approximately $23.9 million and the Company had an accumulated deficit of approximately $154.0 million.

For more information, please refer to the Company’s Form 10-Q filed November 13, 2026, which can be accessed on the SEC website.


FEMASYS INC.
Condensed Balance Sheets
(unaudited)

Assets
 
September 30, 2026
   
December 31,
2025
 
Current assets:
           
Cash and cash equivalents
 
$
23,913,946
     
9,266,353
 
Accounts receivable, net
   
233,778
     
616,600
 
Inventory
   
6,166,371
     
5,740,249
 
Prepaid and other current assets
   
893,098
     
833,133
 
Total current assets
   
31,207,193
     
16,456,335
 
Property and equipment, at cost:
               
Leasehold improvements
   
1,238,886
     
1,238,886
 
Office equipment
   
91,610
     
78,155
 
Furniture and fixtures
   
424,586
     
417,876
 
Machinery and equipment
   
3,125,855
     
3,065,713
 
Construction in progress
   
991,124
     
897,885
 
     
5,872,061
     
5,698,515
 
Less accumulated depreciation
   
(3,991,222
)
   
(3,802,940
)
Net property and equipment
   
1,880,839
     
1,895,575
 
Long-term assets:
               
Lease right-of-use assets, net
   
952,796
     
1,297,121
 
Intangible assets, net of accumulated amortization
   
99,902
     
134,914
 
Other long-term assets
   
946,928
     
940,232
 
Total long-term assets
   
1,999,626
     
2,372,267
 
                 
Total assets
 
$
35,087,658
     
20,724,177
 

(continued)


FEMASYS INC.
Condensed Balance Sheets
(unaudited)

Liabilities and Stockholders’ Equity
 
September 30, 2026
   
December 31, 2025
 
Current liabilities:
           
Accounts payable
 
$
$1,958,546
     
1,830,124
 
Accrued expenses
   
855,377
     
1,265,773
 
Note payable
   
292,229
     
—
 
Clinical holdback – current portion
   
29,250
     
52,644
 
Operating lease liabilities – current portion
   
465,960
     
487,624
 
Total current liabilities
   
3,601,362
     
3,636,165
 
Long-term liabilities:
               
Clinical holdback – long-term portion
   
58,179
     
52,370
 
Convertible notes payable, net
   
3,717,653
     
3,178,864
 
Conversion option liability
   
—
     
2,014,000
 
Warrants liabilities
   
—
     
4,943,000
 
Operating lease liabilities – long-term portion
   
682,302
     
1,030,476
 
Total long-term liabilities
   
4,458,134
     
11,218,710
 
Total liabilities
   
8,059,496
     
14,854,875
 
Commitments and contingencies
               
Stockholders’ equity:
               
Common stock, $0.001 par, 200,000,000 shares authorized, 8,662,139 shares issued and 8,656,277 shares outstanding as of  September 30, 2026; and 2,986,116 shares issued  and 2,980,254 shares outstanding as of December 31, 2025
               

               

               

   
8,662
     
2,986
 
Treasury stock, 5,862 common shares
   
(60,000
)
   
(60,000
)
Warrants
   
19,023,695
     
5,246,150
 
Additional paid-in capital
   
162,069,759
     
146,506,310
 
Accumulated deficit
   
(154,013,954
)
   
(145,826,144
)
Total stockholders’ equity
   
27,028,162
     
5,869,302
 
 
               
Total liabilities and stockholders' equity
 
$
35,087,658
     
20,724,177
 


FEMASYS INC.
Condensed Statements of Operations
(unaudited)

   
Three Months Ended September 30,
   
Nine Months Ended September 30,
 
   
2026
   
2025
   
2026
   
2025
 
Sales
 
$
404,597
     
729,394
     
1,161,313
     
1,479,926
 
Cost of sales (excluding depreciation expense)
   
187,496
     
293,838
     
488,538
     
569,275
 
                                 
Operating expenses:
                               
Research and development
   
1,942,927
     
1,382,022
     
5,199,206
     
5,764,923
 
Sales and marketing
   
943,002
     
1,143,805
     
3,552,755
     
3,037,349
 
General and administrative
   
1,704,091
     
1,477,800
     
5,418,059
     
4,817,485
 
Depreciation and amortization
   
77,091
     
85,697
     
242,172
     
256,835
 
Total operating expenses
   
4,667,111
     
4,089,324
     
14,412,192
     
13,876,592
 
Loss from operations
   
(4,450,010
)
   
(3,653,768
)
   
(13,739,417
)
   
(12,965,941
)
Other income (expense):
                               
Interest income
   
85,610
     
17,315
     
155,131
     
53,488
 
Change in fair value of Conversion Option liability
   
—
     
—
     
1,732,413
     
—
 
Change in fair value of Warrants liabilities
   
—
     
—
     
4,228,000
     
—
 
Interest expense
   
(200,415
)
   
(532,073
)
   
(563,072
)
   
(1,483,022
)
Other expense
   
—
     
(26,295
)
   
—
     
(286,295
)
Total other income (expense), net
   
(114,805
)
   
(541,053
)
   
5,552,472
     
(1,715,829
)
Loss before income taxes
   
(4,564,815
)
   
(4,194,821
)
   
(8,186,945
)
   
(14,681,770
)
Income tax expense (benefit)
   
—
     
—
     
865
     
(4,188
)
Net loss
 
$
(4,564,815
)
   
(4,194,821
)
   
(8,187,810
)
   
(14,677,582
)
                                 
Net loss attributable to common stockholders
 
$
(4,564,815
)
   
(4,194,821
)
   
(8,187,810
)
   
(14,677,582
)
                                 
Basic and diluted loss per share
 
$
(0.53
)
   
(2.05
)
   
(1.59
)
   
(9.25
)
                                 
Weighted-average common shares and pre-funded warrants outstanding, basic and diluted
   
8,660,381
     
2,050,761
     
5,136,109
     
1,586,992
 

About Femasys Inc.

Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed® Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc®, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction.


Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

# # #

Contacts:
IR@femasys.com
Media@femasys.com



Filing Exhibits & Attachments

4 documents

Keep reading